Thoroughbred Financial Services LLC Has $421,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Thoroughbred Financial Services LLC lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 20.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 592 shares of the biopharmaceutical company’s stock after acquiring an additional 102 shares during the quarter. Thoroughbred Financial Services LLC’s holdings in Regeneron Pharmaceuticals were worth $421,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Intact Investment Management Inc. bought a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $356,000. Principal Financial Group Inc. increased its holdings in Regeneron Pharmaceuticals by 1.7% in the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock valued at $181,961,000 after purchasing an additional 2,828 shares during the last quarter. Fagan Associates Inc. lifted its stake in Regeneron Pharmaceuticals by 42.2% in the fourth quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company’s stock valued at $9,205,000 after buying an additional 3,832 shares during the period. Golden State Equity Partners boosted its holdings in Regeneron Pharmaceuticals by 1,479.1% during the fourth quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company’s stock worth $967,000 after buying an additional 1,272 shares during the last quarter. Finally, ABC Arbitrage SA acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $1,510,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

REGN has been the topic of a number of analyst reports. Sanford C. Bernstein cut their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. Citigroup decreased their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. BMO Capital Markets lowered their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a research report on Tuesday, February 4th. Piper Sandler reduced their target price on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a report on Monday, January 27th. Finally, Canaccord Genuity Group downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 17th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $966.88.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $573.45 on Monday. The stock has a market capitalization of $62.69 billion, a PE ratio of 14.98, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44. Regeneron Pharmaceuticals, Inc. has a 52 week low of $565.36 and a 52 week high of $1,211.20. The stock has a 50 day moving average price of $676.70 and a 200 day moving average price of $776.59. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm’s revenue was up 10.3% on a year-over-year basis. During the same period last year, the business earned $11.86 earnings per share. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.61%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.